The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Credits: None available.
Participants will be able to evaluate the impact of lumasiran, a RNAi therapuetic in young children with primary hyperoxaluria type 1 (PH1)- a rare genetic kidney disorder
You must be logged in and own this session in order to